Raclopride
Phase 1Small molecule
Raclopride is one of 2 small molecule programs targeting Clinical High Risk for Psychosis (CHR). It is currently in Phase 1.
1
Indications
5
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Clinical High Risk for Psychosis (CHR)
#DrugCompanyPhaseTrials
1Ritalin
NovartisPhase 1
Raclopride
NNational Institute of Neurological Disorders and Stroke (NINDS)
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Parkinson's Disease1 trial
Brain Injury1 trial
Neural Basis of Decision-Making Deficits in Traumatic Brain Injury
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02169310·45 enrolled
Obesity1 trial
Brain Dopamine Function in Human Obesity
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1·NCT03648892·61 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Raclopride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details